#United States #New Orleans #cancer therapies #ImmunoGenesis #NeauxCancer

ImmunoGenesis at the 2025 NeauxCancer Conference

ImmunoGenesis, a forward-thinking biotech entity operating in the clinical phase, is gearing up to make a significant impact at the upcoming 2025 NeauxCancer Conference. This distinguished event is set to unfold from March 27 to 29 in the vibrant city of New Orleans, organized by the Cancer Advocacy Group of Louisiana (CAGLA). The conference aims to spotlight innovative and emerging players within the biotech and healthcare landscape, particularly those making strides in oncology.

Presentation Insights

During this year's Innovation Track, James Barlow, the President and CEO of ImmunoGenesis, will deliver a presentation detailing the company's ambitious plans to redefine the realm of immuno-oncology. He will share updates on their flagship product, IMGS-001, which is currently undergoing an active Phase 1a/1b clinical study. This innovative treatment is a novel dual-specific PD-L1/PD-L2 antibody, designed to tackle immune-resistant tumors often termed as 'cold tumors'. These tumors pose a significant challenge in current cancer therapies, accounting for over half of all cancers.

Furthermore, Barlow will elaborate on recent developments concerning ImmunoGenesis's second clinical asset, IMGS-101, which is currently being evaluated in a Phase 2 trial. This agent functions as a hypoxia reversal agent and is being tested in conjunction with checkpoint inhibitors to enhance treatment efficacy.

Importance of the Conference

The NeauxCancer Conference is an essential gathering for oncologists and other healthcare practitioners dedicated to advancing cancer treatment methodologies. Attendees will have the opportunity to engage in enlightening discussions surrounding the latest innovations and clinical practices in oncology. The Innovation Track serves as a platform for medical professionals and investors alike to discover cutting-edge technologies for cancer treatment and prevention.

Chadwick K. Landry, Portfolio Manager at Poydras Capital Partners and President of CAGLA, expressed enthusiasm about ImmunoGenesis's participation, citing the expansion of their clinical trial to the Ochsner MD Anderson Cancer Center in southeastern Louisiana. He remarked, "This accolade presents an exceptional opportunity for clinicians and investors to delve into ImmunoGenesis's narrative."

Registration Information

Investors eager to learn more about these groundbreaking advancements can take advantage of complimentary registrations at the conference. For detailed registration procedures, interested parties can follow the link provided: CAGLA Registration Link.

About ImmunoGenesis

ImmunoGenesis is committed to transforming the landscape of immuno-oncology by developing therapies specifically targeting the mechanisms behind immune resistance. Their lead compound, IMGS-001, aims to initiate a robust immune response against cold tumors by overcoming their intrinsic challenges. This company is dedicated to paving the way for more effective treatments that promise to improve the lives of cancer patients.

For more information regarding their innovative therapies and advancements, visit ImmunoGenesis Website.